Lastly, a post-hoc analysis of the aforementioned 26-week trial analyzed biomarkers to assessed insulin sensitivity and beta-cell function
Giunta C, Elioglu NH, Albrecht B, Eich G, Chambaz C, Janecke AR, et al
The chronic activation of the immune system in response to latent viral infection could also lead to sustained mitochondrial damage and dysfunction, contributing to the persistence of symptoms
PLoS One 7:e50630
Exenatide, metformin, or both for prediabetes in PCOS: a randomized, open-label, parallel-group controlled study
Contributed by Akshi Seem, Associate Partner Read More: #PatentLaw #DelhiHighCourt #AccessToMedicine #Pharma #IntellectualProperty #MaheshwariAndCo To view or add a comment, sign in CANADA APPROVES NEW PATENT The Canadian Intellectual Property Office / Office de la proprit intellectuelle du Canada (CIPO) has granted Palisade Bio a patent for its PALI-2108 therapy, a gut-targeted PDE4 B/D inhibitor being developed for ulcerative colitis (UC) and fibrostenotic Crohns disease (FSCD)
